Starch Medical Launches Advanced Laparoscopic Hemostat

By admin On April 29, 2009

Starch Medical Inc (SMI), a San Jose, CA-based medical device manufacturer, announces the introduction of its advanced PerClot™ Laparoscopic hemostat in the European Union and other major international markets. PerClot™ Laparoscopic, a delivery configuration within thePerClot™ Polysaccharide Hemostatic System (PHS), was awarded CE approval in 2008.Perclot™ Laparoscopic is a hemostatic system designed for applications in minimally invasive surgical procedures.

The PerClot™ Laparoscopic system contains a unique instrument for precise delivery of AMP™particles through the laparoscope to the bleeding site. The delivery instrument is easily attached to the PerClot™ bellows dispenser and enables hemostat delivery under direct vision to the wound site for the control of capillary, venous and arterial bleeding. The PerClot™ laparoscopic instrument can be employed in the working channel of a standard laparoscope for the delivery of AMP™ particles.

Absorbable Modified Polymer (AMP™) technology is a sophisticated, proprietary engineering process that modifies plant starch into ultra-hydrophilic, adhesive forming hemostatic polymers.AMP™ materials are biocompatible, absorbable polysaccharides containing no animal or human components.

David Lang, President of SMI, commented “The clinical introduction of PerClot™ Laparoscopic and its proprietary, integrated AMP™ technology represents a unique advancement in hemostatic delivery. The company is pleased to offer surgeons a delivery option which will enhance the control of bleeding in the expanding practice of minimally invasive surgery. The performance features of PerClot™ Laparoscopic were favorably received in pre-introduction evaluations in Europe, Asia and Latin America. Additional clinical studies will be conducted at key medical centers in Europe.”

PerClot™ Laparoscopic, as well as other customized, minimally invasive instruments underdevelopment, will be displayed at the 17th International Congress of the European Association for Endoscopic Surgery (www.eaes-eur.org) in Prague, Czech Republic in June, 2009.

SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. SMI’s proprietary, patent-pending technology platform (AMP™), including powders, foams and films, will focus on the worldwide,multi-billion dollar biomaterial, hemostasis, and wound care marketplace. For additional information, distribution inquiries, and licensing options, please visit www.starchmedical.com.

Contact: David LangTel: 651-270-6660 Starch Medical Inc 2150 Ringwood Avenue • San Jose, CA 95131

Tel: 408-428-9818 Fax: 408-383-9189

info@starchmedical.com